Nationwide survey of HLA haploidentical stem cell transplantation with post-transplantation cyclophosphamide

Nationwide survey of HLA haploidentical stem cell transplantation with post-transplantation cyclophosphamide - AMED PTCY 16

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022684

Enrollment

250

Registered

2016-06-09

Start date

2016-06-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients receiving HLA haploidentical stem cell transplantation with post-transplantation cyclophosphamide

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who receive HLA-haploidentical stem cell transplantation between 2012 and 2015

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
1. Engraftment 2. The incidence and severity of acute and chronic GVHD 3. Non-relapse mortality 4. The incidence of relapse 5. Disease-free survival 6. Dose and Timing of post-transplantation cyclophosphamide 7. The proportion of patients who need dose reduction or stop of post-transplantation cyclophosphamide 8. Immunosuppressive drugs except for post-transplantation cyclophosphamide 9. The proportion of patients who stopped immunosuppressive drugs within 1 year. 10. The incidence of cardiac toxicity from post-transplantation cyclophosphamide 11. The incidence of hemorrhagic cystitis 12. The incidence of complications associated with haploimmunostorm syndrome 13. The incidence of donor cell-derived hematological malignancies 14. Medical care cost and duration of hospital stay 15. Subgroup analysis according to stem cell source, conditioning regimen, and GVHD prophylaxis 16. Subgroup analysis according to disease risk index (DRI)	—

Measure

Time frame

1. Engraftment 2. The incidence and severity of acute and chronic GVHD 3. Non-relapse mortality 4. The incidence of relapse 5. Disease-free survival 6. Dose and Timing of post-transplantation cyclophosphamide 7. The proportion of patients who need dose reduction or stop of post-transplantation cyclophosphamide 8. Immunosuppressive drugs except for post-transplantation cyclophosphamide 9. The proportion of patients who stopped immunosuppressive drugs within 1 year. 10. The incidence of cardiac toxicity from post-transplantation cyclophosphamide 11. The incidence of hemorrhagic cystitis 12. The incidence of complications associated with haploimmunostorm syndrome 13. The incidence of donor cell-derived hematological malignancies 14. Medical care cost and duration of hospital stay 15. Subgroup analysis according to stem cell source, conditioning regimen, and GVHD prophylaxis 16. Subgroup analysis according to disease risk index (DRI)

—

Countries

Japan

Contacts

Public ContactJunichi Sugita

Hokkaido University Hospital Department of Hematology

sugitaj@med.hokudai.ac.jp011-706-7214

Outcome results